Regulatory and health technology assessment advice on post‐licensing and post‐launch evidence generation is a foundation for lifecycle data collection for medicines

11 March 2020 - The understanding of the benefit risk profile, and relative effectiveness of a new medicinal product, are initially ...

Read more →

Registry-data – of sufficient quality – are suitable for the extended benefit assessment of drugs

24 January 2020 - Rapid report shows how routine practice data should be collected and processed. ...

Read more →

IQWIG Autumn Symposium 2015: presentations now online

5 January 2016 - Real world data: a gain for benefit assessments? This question was the focus of the Autumn Symposium ...

Read more →